StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$22.15−0.78 (-3.40%)

Close on Nov 20, 2026Market cap $443.25MP/E –Yield –

Neurogene free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Neurogene's free cash flow for the twelve months ending Jun 30, 2026 was -$87.71M. For fiscal 2025 it was -$78.36M. The highest annual figure on record is -$7.24M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$78.36M–
FY2024Dec 31, 2024-$71.41M–
FY2023Dec 31, 2023-$51.74M–
FY2022Dec 31, 2022-$55.05M–
FY2021Dec 31, 2021-$50.82M–
FY2020Dec 31, 2020-$26.79M–
FY2019Dec 31, 2019-$16.27M–
FY2018Dec 31, 2018-$31.63M–
FY2017Dec 31, 2017-$45.21M–
FY2016Dec 31, 2016-$30.94M–
FY2015Dec 31, 2015-$20.29M–
FY2014Dec 31, 2014-$17.60M–
FY2013Dec 31, 2013-$7.83M–
FY2012Dec 31, 2012-$7.24M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.12M–
Q1 FY2026Mar 31, 2026-$26.40M–
Q4 FY2025Dec 31, 2025-$17.56M–
Q3 FY2025Sep 30, 2025-$19.64M–
Q2 FY2025Jun 30, 2025-$19.61M–
Q1 FY2025Mar 31, 2025-$21.55M–
Q4 FY2024Dec 31, 2024-$17.61M–
Q3 FY2024Sep 30, 2024-$15.73M–
Q2 FY2024Jun 30, 2024-$16.35M–
Q1 FY2024Mar 31, 2024-$21.72M–
Q4 FY2023Dec 31, 2023-$17.10M–
Q3 FY2023Sep 30, 2023-$11.65M–
Q2 FY2023Jun 30, 2023-$9.41M–
Q1 FY2023Mar 31, 2023-$13.58M–
Q4 FY2022Dec 31, 2022-$19.37M–
Q3 FY2022Sep 30, 2022-$9.61M–
Q2 FY2022Jun 30, 2022-$11.53M–
Q1 FY2022Mar 31, 2022-$14.54M–
Q4 FY2021Dec 31, 2021-$12.56M–
Q3 FY2021Sep 30, 2021-$9.34M–
Q2 FY2021Jun 30, 2021-$14.47M–
Q1 FY2021Mar 31, 2021-$14.45M–
Q4 FY2020Dec 31, 2020-$9.88M–
Q3 FY2020Sep 30, 2020-$599.00K–
Q2 FY2020Jun 30, 2020-$9.77M–
Q1 FY2020Mar 31, 2020-$6.55M-171.5%
Q4 FY2019Dec 31, 2019-$5.42M–
Q4 FY2018Dec 31, 2018-$9.78M–
Q3 FY2018Sep 30, 2018-$15.37M–
Q2 FY2018Jun 30, 2018$9.15M–
Q1 FY2018Mar 31, 2018-$15.63M–
Q4 FY2017Dec 31, 2017-$11.62M–
Q3 FY2017Sep 30, 2017-$11.56M–
Q2 FY2017Jun 30, 2017-$10.65M–
Q1 FY2017Mar 31, 2017-$11.39M–
Q4 FY2016Dec 31, 2016-$9.09M–
Q3 FY2016Sep 30, 2016-$7.74M–

More Neurogene figures

See a number that looks wrong?